clinical supply News
-
Thermo Fisher Scientific Expands Clinical Supply Chain Services in Europe
To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher Scientific has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new sites will bring much-needed clinical supply chain continuity and specialized cold chain and cryogenic expertise across Europe and globally. Today's ...
-
Matica Bio Opens New Cell & Gene Therapy GMP Facility in Texas
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other ...
-
Thermo Fisher Scientific Enhances Leading Pharma Services Offering by Expanding API Manufacturing Capabilities
Thermo Fisher Scientific, the world leader in serving science, announced the expansion of its API manufacturing capabilities following the completion of its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility from GlaxoSmithKline (GSK). Approximately 400 employees at the Cork, Ireland, site will become part of Thermo Fisher’s Pharma Services ...
-
Thermo Fisher Scientific To Showcase Investments and Innovation at DCAT Week 2021
This week, Thermo Fisher Scientific will highlight its investments and innovations over the past 12 months across its global pharma services network, which have been focused on areas of accelerated demand including cell and gene therapy, drug product development, biologics manufacturing and clinical supply chain services. These highlights will be showcased this week at Virtual DCAT Week. "This ...
-
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings
A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates. The comprehensive offering now includes Clinical Site-to-Patient, Pharmacy-to-Patient and Depot-to-Patient services to enable clinical trial medication delivery directly to patients' homes. Thermo ...
-
Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
-
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
endpoint and THREAD Simplify DCT Operations for Key Stakeholders to Reduce Study Timelines
endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and THREAD, a leading technology and service provider enabling decentralized clinical trials (DCT), have announced their partnership to offer sponsors and sites a solution that simplifies DCT operations and reduces research study timelines. “Adoption of DCT technologies that are capable ...
-
Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
-
Thermo Fisher Scientific Showcases Investment and Innovation During CPhI Worldwide 2021
At CPhI Worldwide 2021, Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics. CPhI 2021 begins with a virtual conference through November 5, 2021 and an ...
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma ...
-
Matica Biotechnology, Inc. Announces Master Research Agreement with Texas A&M
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC). The agreement ...
-
Matica Biotechnology, Inc. Announces Groundbreaking for New GMP Facility
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at ...
-
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell ...
-
Matica Biotechnology, Inc. Announces Plans to Construct GMP Facility for Viral Vector Production
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft2 facility will commence in Q4 2020 and will be dedicated to the ...
-
Endpoint Clinical and Berlinger Collaborate to Provide Complete Visibility of the Historical Temperature Journey of an IMP
Endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Berlinger & Co. AG, specializing in the production of innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and medical industry, have announced their partnership to provide complete end to end visibility of the entire temperature history ...
-
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to ...
-
GI Innovation enters into clinical collaboration with AstraZeneca to explore Immuno-oncology GI-101 • Imfinzi® Combination Therapy
GI Innovation, Inc., (CEO, Jun Ho Hong) announced that GI Innovation signed a clinical supply collaboration agreement with global biopharmaceutical company AstraZeneca for development of GI-101 and Imfinzi® combination therapy. Under this agreement, GI Innovation and AstraZeneca will conduct a clinical trial assessing triplet combination regimen of GI-101, Imfinzi® (durvalumab) and ...
-
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021. Recent Highlights & Accomplishments: Received approval from the Food and Drug ...
By Senseonics
-
Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology
Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you